Podcasts about Glucagon

Send us a textDeep dive into how ketogenic diets and carbohydrate intake effect exercise performance, and misconceptions in sports nutrition.TOPICS DISCUSSED:Insulin as a powerful metabolic hormone: regulates nutrient storage across tissues, overriding others like glucagon to promote fat and glucose storage during abundance.Glucagon & GLP-1 roles in metabolism: Glucagon mobilizes liver glucose during scarcity; GLP-1, amplified in drugs like Ozempic, suppresses hunger but originated as a diabetes treatment.Transition to ketosis in fasting or low-carb diets: Low insulin enables fat breakdown into ketones for brain fuel, allowing survival for weeks without food, with adaptation taking about four weeks.Hypoglycemia vs. glycogen depletion: Low blood sugar causes fatigue and irritability due to brain energy deficit, while muscle glycogen levels do not directly limit performance.Ketogenic diets & exercise performance: Studies show no difference in endurance after adaptation, with some athletes performing better on low-carb due to enhanced fat oxidation.High-carb diets in athletes: In one study, about 30% developed prediabetes-like fasting glucose elevations, linked to total carb intake, despite leanness and fitness.Misconceptions in sports nutrition: Guidelines recommend 60-90g carbs/hour, but evidence shows 10g suffices to maintain blood sugar and performance, avoiding insulin spikes that impair fat use.Individual variability in diet response: Athletes vary in optimal fuel sources; it's possible to by athletic and lean but also metabolically unhealthy.PRACTICAL TAKEAWAYS:For workouts over ~60 minutes, consume ~10g carbs per hour (e.g., a third of a banana) to maintain blood sugar and prevent fatigue, regardless of overall diet.Allow at least four weeks for adaptation when trying a ketogenic diet, enabling the body to fully transition to the ketogenic state.Monitor personal responses to carb intake, as high levels can elevate fasting glucose even in fit individuals; consider lower-carb options if experiencing metabolic issues.Prioritize metabolic flexibility through varied diets or fasting periods to improve energy stability, but consult resources for proper formulation to support health.ABOUT THE GUEST: Andrew Koutnik, PhD earned a PhD in biomedical sciences with a focus on exercise physiology and metabolic health, informed by his personal diagnosis of type 1 diabetes in childhoodSupport the showAffiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

Glucagon-like peptide-1 (GLP-1) can transform metabolic health, but only with smart dosing, adequate dietary protein, regular strength training, and mental health support. In this episode, we explore how GLP-1 medications work in the brain and gut, why metabolic health is more than BMI or a weight on the scale, and how to use these drugs safely. Our expert guest, gastroenterologist, Dr Supriya Rao shares practical dosing, side effect strategies, and what makes results stick.• Defining metabolic health beyond BMI and weight• How GLP-1s reduce appetite and slow gastric emptying• Healthy weight loss pace and preserving lean muscle• Practical + science-backed dosing and individualized titration• The unknown risks of compounding and microdosing• Managing nausea, reflux, and constipation• Diet shifts: smaller meals, more fiber, adequate protein• Mental health, body image, and stigma in care• Durability of results and maintenance dosing• New indications: MASH (metabolic dysfunction-associated steatohepatitis), sleep apnea, cardiovascular protection• Building an educated care teamReferences/Resources:Tzang CC, Wu PH, Luo CA, Chen ZT, Lee YT, Huang ES, Kang YF, Lin WC, Tzang BS, Hsu TC. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025 Nov 28;90:103680. Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127. Published 2024 Aug 31. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025 Jul 17;86:103363. Integrated Gastroenterology Consultants (Dr. Supriya Rao's practice site)Book: The GLP-1 Kitchen: A Cookbook for Living Well on Weight Loss Medications Escobar S-N et al. (contains affiliate marketing link)Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

N503 - EASD 2025 - Glucagon: Ganha novo papel nas terapias para diabetes e obesidade - Fernando Valente e Luciano Giacaglia by SBD

Un nouvel épisode du Pharmascope est disponible! Dans ce 168e épisode, Nicolas, Isabelle et Olivier discutent de la prise en charge du diabète de type 2…et on apprend une triste nouvelle! Les objectifs pour cet épisode sont les suivants: Discuter des bénéfices et des risques des cibles d'hémoglobine glyquée dans le diabète de type 2 Discuter des caractéristiques principales des médicaments utilisés dans le traitement du diabète de type 2 Discuter des bénéfices et des inconvénients des inhibiteurs du SGLT-2 et des analogues du GLP-1 Ressources pertinentes en lien avec l'épisode Qaseem A, et coll. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569-576. Zoungas S, et coll; Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Nong K et coll. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025 Aug 14;390:e083039. Zelniker TA et coll. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23;139(17):2022-2031. Silverii GA et coll. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024 Mar;26(3):891-900. Yoshida Y et coll. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis. J Diabetes Complications. 2022 Aug;36(8):108255. Chiang CH et coll. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025 Nov;169(6):1268-1281. Neuen BL et coll. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024 Nov 26;150(22):1781-1790. GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. Glycemia Reduction in Type 2 Diabetes – Glycemic Outcomes. N Engl J Med. 2022 Sep 22;387(12):1063-1074. Marso SP et coll; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. PEER : Diabetes Medication Decision Aid

Welcome back to Ozempic Weightloss Unlocked, the podcast where we break down the latest developments in weight loss medications and what they mean for your health. I'm your host, and today we're diving into some significant news that just dropped.Just yesterday, the World Health Organization released a major guideline on Glucagon-like Peptide-1 therapies, commonly known as GLP-1 drugs like Ozempic and Wegovy. This is a big deal. The WHO is now recommending that adults living with obesity can use long-term GLP-1 therapies for weight management. This conditional recommendation comes with moderate-certainty evidence showing these drugs are effective at achieving meaningful weight loss and providing broad metabolic benefits.But here's what's interesting: the WHO isn't just saying take the medication and you're done. They're emphasizing that people prescribed these drugs benefit significantly from structured behavioral therapy. This includes goal setting for physical activity and diet, energy intake restriction, regular counseling sessions, and ongoing progress assessment. So it's not just a pill and forget it approach. You need the full package.Now, many of our listeners are probably wondering about something that's been trending lately: muscle loss. And this is important. Research shows that rapid weight loss from these medications can decrease your overall muscle mass. But here's the good news: this isn't caused by the drug itself. It's related to the process of losing weight. The key to managing this is focusing on protein intake, staying hydrated, and engaging in strength training. In fact, consistent strength training can lead to improvements in muscle growth within two to three months.Experts recommend eating between 0.8 and 1 gram of protein for each kilogram of body weight daily. And if you're losing weight on a GLP-1 medication, a registered dietitian can help you dial in exactly what you need. Researchers are also actively working on new medications that could preserve muscle mass while you're losing fat, so we may see even better solutions down the road.The bigger picture here is that obesity affects more than one billion people worldwide, and for the first time, we're seeing a reduction in obesity rates in the United States, largely thanks to these medications and people's commitment to using them responsibly.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure you subscribe so you don't miss our next episode where we'll explore more of the latest breakthroughs in weight loss science. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Weight-loss drugs like Ozempic may be doing more than trimming waistlines. Early research shows they could also curb cravings for alcohol, opioids and nicotine. Glucagon-like peptide-1 receptor agonists, or GLP-1RAs,...

Welcome to Ozempic Weightloss Unlocked, the podcast where we break down the latest developments in semaglutide medications and what they mean for your health. I'm your host, and today we're diving into the most important updates from 2025.Let's start with what's working. Ozempic continues to demonstrate significant effectiveness for weight loss, producing mean weight reduction of fourteen point nine to seventeen point four percent over sixty eight weeks in people without diabetes. The higher dose formulation, known as Wegovy, shows even more impressive results, with studies consistently showing greater average weight loss compared to the lower doses found in Ozempic. For millions managing type two diabetes or seeking weight management solutions, these medications have become game changers.But here's what listeners need to know right now. Recent research is raising important safety concerns that demand our attention. A June 2025 study published in JAMA Ophthalmology found that patients taking semaglutide were twice as likely to develop neovascular age related macular degeneration, a condition that gradually destroys central vision. While the absolute risk remains small, researchers from the University of Toronto identified this link as statistically significant. The mechanism makes sense too. Semaglutide alters vascular and inflammatory pathways directly implicated in macular degeneration.The vision concerns aren't the only ones. A January 2025 study in JAMA Otolaryngology found that patients initiating Glucagon like Peptide One receptor agonist therapy had a significantly increased risk of thyroid cancer diagnosis within the first year of use compared to other diabetes medications. Researchers analyzed data from over three hundred fifty thousand adults with type two diabetes.Then there's gastroparesis, the stomach paralysis condition that's become central to ongoing litigation. Multiple lawsuits allege that Novo Nordisk, the manufacturer, failed to provide adequate warnings about this risk. The lawsuits argue the company knew or should have known about the potential link based on clinical studies and medical literature. Patients reported persistent vomiting, nausea, and extreme stomach discomfort after starting the medication.The legal landscape shifted in December 2024 when the Judicial Panel on Multidistrict Litigation ruled to expand the Glucagon like Peptide One receptor agonist lawsuit to include claims involving Saxenda, though blood clot related injuries were excluded due to complexity concerns.What does this mean for you? If you're considering Ozempic or Wegovy, talk to your doctor about these emerging risks alongside the proven benefits. If you're already taking these medications and experiencing vision changes, thyroid issues, or stomach problems, document everything and consult your healthcare provider.The story of Ozempic isn't finished. As evidence emerges, companies face questions not just about what they disclosed but about what they should have investigated. The scientific community continues watching as more data arrives.Thank you so much for tuning in to Ozempic Weightloss Unlocked. Please subscribe to stay updated on the latest developments in semaglutide research and safety updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Dr. Graham interviews Dr. Troy Amen regarding his paper "Glucagon-like Peptide-1 Agonists and Common Hand Procedures: Perioperative and Postoperative Risks and Complications" which is the lead article in the November 2025 issue of the Journal of Hand Surgery

GLP-1 Agonists (Glucagon Like Peptide 1 Agonists) such as Mounjaro and Wegovy are becoming more widely used, here we cover examples of GLP1 Agonists, mechanism of action, as well as GLP1 agonist side effects. PDFs Available at: www.rhesusmedicine.com Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What are GLP-1 Agonists? 0:23 GLP-1 Agonist Mechanism of Action1:35 GLP-1 Agonist Indications & Uses2:37 GLP-1 Agonist Examples 4:05 GLP-1 Agonist Side EffectsPlease remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. ReferencesManne-Goehler, J., Franco, J., 2025. Side effects of GLP-1 receptor agonists. BMJ, 390:r1606. [online] Available at: https://www.bmj.com/content/390/bmj.r1606.full. (bmj.com)Collins, L., 2024. Glucagon-like peptide-1 (GLP-1) receptor agonists. StatPearls. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/. (NCBI)Andreasen, C.R., Andersen, A., Knop, F.K. & Vilsbøll, T., 2021. How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 10(7). [online] Available at: https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml. (ec.bioscientifica.com)Diabetes UK, 2025. GLP-1 agonists – tablets and medication. [online] Available at: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1. (Diabetes UK)

Today we're talking about peptides being researched for addiction. We'll unpack the science behind the incretin system, how those pathways tie into reward and substance use, and focus in on the newest triple‐agonist retatrutide. We'll also look at early evidence for alcohol, tobacco and other substance-use disorders when using certain peptide therapies. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ What are GLP-1, GIP and the “dual/triple” agonists? First, let's review some biology to ground the discussion. GLP-1 (glucagon‐like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones. Incretins are gut hormones that help with digestion and blood sugar control. They're released by the gut in response to food.  GLP-1 raises insulin levels after you eat to help lower blood sugar, slows gastric emptying, and reduces appetite. It also reduces how much glucagon your body makes. This helps to lower your blood sugar. Medications like semaglutide and dulaglutide work by mimicking GLP-1 and are often referred to as “GLP-1 agonists”. GIP has somewhat overlapping but distinct roles from GLP-1. It too, influences insulin secretion, but it also helps with fat metabolism.  In a nut shell, GIP helps fat cells respond more efficiently to insulin so they release stored fat to be used as energy when your body needs it. This process helps your metabolism shift from just storing energy to burning fat for fuel. Medications like tirzepatide work by mimicking both GLP-1 and GIP and are often referred to as “dual” agonists.  When GIP and GLP-1 are activated together — like in tirzepatide — they work as a team: GLP-1 helps control appetite and slow down digestion. GIP boosts how your body handles insulin and energy. Together, they help reduce hunger, improve metabolism, and burn fat more efficiently. Now here's where it gets a bit tricky.  A newer medication that's still in development, retatrutide, works on three hormone pathways: GLP-1, GIP, and glucagon receptors. It's called a “triple agonist”, and even though it activates the glucagon receptor, it doesn't cause high blood sugar like you might expect. It's about balance. In type 2 diabetes and obesity, the body's hormone signals are out of balance. Retatrutide gently activates the glucagon receptor, but at the same time it strongly activates GLP-1 and GIP receptors — which still help control blood sugar and increase insulin. So blood sugar stays stable or even improves overall. Glucagon doesn't just affect blood sugar — it also increases metabolism and helps the body burn fat and calories. By slightly stimulating glucagon receptors, retatrutide can boost energy use and promote fat loss without causing big spikes in blood sugar. As a result, you get the blood sugar control of GLP-1 and GIP, plus the fat-burning benefits of glucagon activation — leading to even greater weight loss and metabolic improvement.  Right now, retatrutide is in phase 3 clinical trials, which are the final stage of testing before approval. These studies are expected to finish in early 2026, and if results look good, the FDA could approve retatrutide as early as 2027.  Addiction Why is this relevant for addiction? Because the gut-brain axis, reward circuitry, and the pathways that regulate “wanting/consuming” food overlap with those involved in substance use.  Appetite, reward, and craving may share neural substrates (dopamine, GABA, mesolimbic system) and so a drug that reduces drive to eat might also modulate drive to drink, smoke or use other substances. The link between GLP-1/related drugs and substance use disorders  Let's now dive into what the research says about GLP-1 receptor agonists (and related medications) in the context of alcohol, tobacco, and other substances. Let's start with what we know from animal research. In pre-clinical studies, scientists have found that GLP-1 receptor agonists seem to change how animals respond to addictive substances. A systematic review showed that in rodents, treatment with GLP-1 drugs reduced the behavioral effects of alcohol, nicotine, amphetamine, and cocaine. For example, one GLP-1 drug called exendin-4 reduced alcohol-related behaviors in rodents. And even more recently, a study in both male and female rats showed that giving semaglutide, tirzepatide, or even retatrutide, reduced alcohol discrimination, meaning the rats didn't experience the same “feeling” from alcohol as before. This means that the “interoceptive stimulus effects” or the internal sensations — how alcohol feels inside the body, changed. This is really important because this is what often drives people to drink or relapse. So, if these medications can blunt those internal cues, it suggests they might disrupt the rewarding effects of alcohol that help maintain addiction. When we shift to human studies, things get even more interesting. A systemic review found that out of five studies looking at GLP-1 receptor agonists in people with substance use disorders — mostly alcohol and nicotine — three showed real reductions in substance use, while two did not. In one large observational study of over 150 adults with obesity who drank alcohol, those who were taking semaglutide or tirzepatide for at least 30 days reported fewer drinks, fewer binge episodes, and lower overall intake compared to people not on those drugs. A phase 2 clinical trial of once-weekly semaglutide in adults with alcohol use disorder showed similar results — lower alcohol craving and some reductions in drinking behavior. There's also data from a massive registry-based study showing that people with alcohol or opioid use disorder who were prescribed GLP-1 or GIP drugs had 50% lower rates of alcohol intoxication and a 40% lower rate of opioid overdose. Still, experts are cautious — meta-analyses and reviews consistently note that the evidence, while promising, is still early and we don't yet have large, long-term randomized controlled trials. What's Going On? So, what's actually happening inside the brain and body that could explain these changes in craving and reward? How can medications originally made for diabetes and/or weight loss end up helping with addiction?” Mechanistically, GLP-1 drugs may affect the brain's reward system — especially dopamine signaling in areas like the nucleus accumbens — and reduce the “wanting” of reward substances like food or alcohol. They might also calm stress responses and make relapse cues less powerful. And there are probably some physical effects too — things like slower digestion and increased fullness, which might make it harder to physically consume large amounts of alcohol or even smoke as much. But again, many of these findings come from animal models, which don't always perfectly reflect human addiction. Most of the focus so far has been on alcohol, though there's also some early evidence that GLP-1 drugs might influence nicotine use. For substances like opioids or cocaine, the data is thinner and more mixed. Bottom line — at this stage, GLP-1 receptor agonists, and maybe even GIP/GLP-1 dual agonists, represent a really promising new direction for treating addiction — but it's still early days. We also don't yet have human addiction studies on retatrutide, pre-clinical data in rats show that, like semaglutide and tirzepatide, it too, reduces alcohol discrimination. In practical terms, if you're treating patients with obesity or diabetes who also struggle with alcohol or nicotine use, choosing a GLP-1 or dual agonist might offer an unexpected bonus — helping with cravings. It also gives us a new way to talk with patients about how metabolism, reward, and craving are all interconnected. But — and this is important — the data are still limited. Most studies are small, short, and often focus on people with obesity or metabolic disease rather than pure addiction. So, for now, it's an adjunctive idea, not a replacement for established therapies. We'll need larger randomized trials in people with substance use disorders to really understand who benefits, what doses work, and how long the effects last. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.

The gut is in the news. It's really in the news. Catapulted there from exciting developments coming from laboratories all around the world. Links of gut health with overall health are now quite clear and surprising connections are being discovered between gut health and things like dementia and Alzheimer's. But how does the gut communicate with other parts of the body in ways that make it this important, and where does the brain figure into all this? Well, there's some interesting science going on in this topic, and a leading person in this area is Dr. Diego Bohorquez. Dr. Bohorquez is the associate professor of medicine, of molecular genetics and microbiology and of cell biology at the Duke University School of Medicine. Interview Transcript Diego, your bio shows that you blend work in nutritional biochemistry, gastrointestinal physiology, and sensory neurobiology. It took me a little time to figure out just what these things are, but what this represents, to be a little more serious, is a unique ability to understand that the different parts of the body, the gut and the brain in particular, interact a lot. And you're in a very good position to understand how that happens. Let's dive in with the kind of a basic question. What got you interested in this interaction of the gut with the brain and why care about it? Yes. Kelly, I think that that's all technicalese for saying that we are at the interface of food, the gut, and the brain. Apart from the fact that we are what we eat and if we truly believe that then food will be shaping us. Not only our body, but also like our belief systems, our societal systems, and so on and so forth. I don't think that that is anything new. However, what is new is the ability of the gut to guide our decision making. And it was interesting to hear in your introduction that now the gut is all in the news. In 2005 when I came to the United States, and I was at North Carolina State University, and I joined a graduate school. I remember taking a graduate course in physiology in 2007. And when the professor opened the session on gastrointestinal physiology, he said the gut is one of the most misunderstood and mysterious organs. It has almost as many neurons as the spinal cord, or more. But honestly, we don't give a lot of respect to the gut. We only think that it does some digestion and absorption, and we judge it more for the value of its products of digestion than what it does for the entire body. And fast forward almost 20 years later now, partly my laboratory and other laboratories that have entered this field since some of our discoveries started to emerge, it's very clearly showing that the gut not only has its own sensory system that is behind what we call gut feelings. The gut feelings are actually real. But it actually can influence our decision making. Like specifically, we have shown that our ability to choose sugars and consume sugars and feel sugars and choose them over sweeteners, it can be pinpointed to a specific set of cells in the intestine called neuropod cells and specific receptors in those cells. And the intestine is right after the stomach. And this is where these cells are exposed to the surface of the gut and detect the chemical composition of food to guide our decision making. Let's talk about that a little bit more. So, you've got this axis, or this means of communication between the gut and the brain going on. And let's talk about how it affects what we eat. You just alluded to the fact that it's pretty important. What does it tell us? What to eat, how much to eat? What we like to eat? When we're hungry, when we've had enough? How does this affect our eating? We are beginning to understand how much it affects this eating. And obviously we are departing from understanding, right? And an understanding is cognitive. In the 1500s is when the idea of 'we think therefore we are,' came online. And we needed to think things before we actually will understand them. But well before thinking them, we actually feel them. And you probably have noticed that. If anybody offers you maybe a cup of water at 5:00 AM, 6:00 AM, it will be very welcome. Especially with it's a little bit warm. If they offer you a steak at 5:00 AM you will run away from that. But in fact, you'll create distress I think unless you are like severely jet lagged. And a lot of those feelings not only come from the experience, but even if you blind are blindfolded, your gut will be able to evaluate what you just ingested. And it is because the intestine, it is the point where those molecules in the meal or in the drink, will be either absorbed to become part of who we are, or will be excreting and expelled. And that absorption of who we are is dependent on the context. Like for instance, the part of the month, morning versus afternoon, health status, age, will influence specifically like at the molecular level, what it is that we need to continue to thrive. It sounds like there's lots of potential for the gut and its interaction with the brain working in concert with the rest of the body. Things are in balance and working like they should be. But there are lots of things going on out there that disrupt that. Tell us more about that and how it affects eating. For example, the levels of obesity have risen so much in the past decades. How does the gut figure into that, for example. Could there be environmental things like the microplastics or exposure to toxins like pesticides and things that might be affecting the gut that throws the system off? I think that that is a very timely question for the days. Over the last 10 years, we have documented that the gut has its own sensory system. And in fact, it's one of the most ancient sensory systems. At the very beginning, 600 million years ago, when cells started to coalesce into animals, multicellular organisms, they needed to eat. And they needed to not only find the food but create a sensory representation of the food. What do I mean by that? Eating algae is very different than eating bacteria, for instance. And the gut needed to have these sensors to be able to rapidly create first a representation, this is bacteria. And then put out the molecules to digest that bacterium or those bacteria. And then ultimately absorb them, turn them into metabolites and continue to thrive, right? Perhaps reproduce, coalesce and so on and so forth. This is a very important concept because our reality, the reality that you and I are having right now, it is guided by our senses. And we have multiple senses. Like for instance, we are able to communicate partly because of the sound that is going through our ears. And then there are inner hair cells that are picking up those waves. Passing that information to the brain, decoding it, and then the brain coalesces with everything else and saying like, 'okay, Diego, you're in a podcast. Make sure that you say something hopefully reasonable, right?' What the gut is doing, as a true sensory system, is also detecting the food that we have ingested, creating a rapid representation. It's not the reality itself. It is a representation of the reality. Because when we eat an apple, ultimately the gut, what it's doing is creating a representation that was an apple and not an orange. And then telling the brain, look, you're going to get some glucose, some fiber, a little bit of a skin. And you may need to adjust it with water, right? And then that will trigger the desire to, 'oh, maybe I should have also a cup of water.' Why does that have to do with, the societal issues that we are facing? Since the 1970s, we learned to disentangle the sensory experience of food, not only as humans or scientists, but also that was extrapolated to the society. So, if you go and look, and it is not a secret, it has been very well documented. For instance, the ability to put artificial sweeteners out there. It has really changed the health landscape. And it was just a normal progression of how it is that we humans think. We thought well, people consume sugars because they're sweet. If we take out the calorie and we just leave the sweetness, it will be totally fine because it's benign. You're not consuming anything else. However, the gut, you have promised the gut something sweet. That it has always, or almost always, invariably, been associated with a nutritional value. Then the gut is fed this information that is skewed. Then it has to go and adjust. And we actually have demonstrated that in the laboratory that when the neuro pods detect a non-caloric sweetener, they actually release a different neurotransmitter that communicates to the brain that artificial sweeteners have arrived at the gut, as opposed to glucose, which triggers the release of glutamate. And that glutamate is essential for the organism to know that we have consumed sugar. Is it safe to say then that the body has evolved to be able to have effective signaling and feedback systems with things that are found out there in nature, like sugar or an apple or an orange. But when you start introducing things that don't exist in nature, like the artificial sweeteners, then bad things can happen. Yes. Because imagine right now your brain will swap the reality and you will transport yourself or the beach. You may not even have the clothing ready to confront the breeze of the beach, right? Or the salt. You would have not been prepared, right? We evolved around nature because nature was there before us. Therefore, we had gradually adjusted to what nature had to offer. Eventually we introduced fire, and we were able to transform simple or complex carbohydrates into something digestible. And then the body had the ability to adjust to it. And not only the body, but also the microbiota in the gut. Now we are talking about like the transformation of foods. And especially I think in the last 30 years we have been able to transform those foods. Beverages have sweeteners now. We have energy drinks that have a composition of vitamins and other things. And while those things individually perhaps are not innocuous, we haven't explored what is the conglomerate effect on long-term health. When we talk about these things being added to foods, I mean, there are whole classes of things like colorings and dyes and artificial sweeteners and things. And then there are processing things that go on, like extrusion and different things that take something like wheat or corn and turn it into something that the body is not accustomed to dealing with. Is the body incapable of perceiving what these things are? Does it get send out wrong signals? Why should we be worried about these things? I don't think that we should be worried necessarily because that's alarming, right? But we should be aware, certainly, that the body keeps tabs on it. Something very simple. If you rub water on your skin versus if you rub oil on your skin, your brain already starts to perceive that substance as different. Now, imagine the gut is going to know exactly the same thing. It knows what water is. It knows what oil is. It knows what carbs are. It knows what protein is. And depending on what it has been fed for, thousands of years, it will be able to create that representation as I alluded to. And therefore, if there is a foreign composition, it's going to have to adjust to the situation. And that is how you can end up altering the composition of a regular body. Because like, for instance, in nature if you go and look at native populations that live very close to nature, you know, the body composition is in a certain form. But in cities where you're exposed to foods that have been transformed, the body composition is very different. And I'm not talking only about body weight, but also height, shape, you know. That certainly makes sense. You know, something that's been in the news a lot lately are the GLP1 drugs like Ozempic and Zepbound and they have very powerful effects on appetite, satiety, and weight regulation. How is the gut brain axis involved in this? I would like to make a couple of points in there.The first one is that glucagon-like peptide is obviously is very similar to glucagon. Glucagon is produced in the pancreas. Glucagon-like peptide is actually produced in the gut. And it is produced by these neuro pod cells that also produce some neurotransmitters. And it is produced in response to specific nutrients like glucose. And it is a signal glucagon like peptide 1. It is a signal for not only adjusting insulin release, but it is also a signal for coordinating what has arrived in the gut. It does affect motility. Eventually it is thought that goes into the bloodstream and affects the nervous system. However, and I said it is thought because the brain also produces glucagon-like peptide. There are cells in the skin. There are cells in the urethra. There are cells in the bladder. There are cell cells in the spinal cord in the choroid plexus that is exposed to the cerebral spinal fluid that also produces some of these peptides as signaling molecules. And I have to make that clarification because traditionally it has been thought to be a signal from the gut, per se. But these are just signaling molecules. The second part is that the arrival of Ozempic, I thought that it was obviously a very important step not only scientifically, but also societally. Why? Because up until 1980s and I have thought with many colleagues especially in medicine. And they will say like, when an obese patient will arrive in the office, first of all, there was not a lot of options. One of the recommendations is - are you doing enough dieting or exercise? And if the patient was like, you know, I'm not eating even a lot, but I'm gaining weight. Or it was perhaps psychosomatic because we didn't have the molecular language to be able to explain what was going on. I think that Ozempic clearly has shown that when we are affecting a set of receptors in the body, perhaps in the gut, it's changing many different things. Not only like food intake, but also alcohol intake and how people feel. I think that is definitely a breakthrough. Where are we going from here? I think that this is the beginning of a long conversation in which we are going to be looking for options not only to reduce the amount of food, but actually to steer food choices from the gut. Because the gut is still as an external surface. And that's what I've mentioned that the discovery that these neuro pot cells can guide our food choices, I think that is very attractive for future options on how we are going to steer decision making. So, let me ask a final question. You partly just answered it, but where do you see this field going? What are you excited about and what do you think the next frontiers will be? I think that I'm a little bit more close to nature. I think that on moving forward, there's all obviously a lot of technologies and molecules that are going to be developed to perhaps treat some disorders. Not only related to the body, but also to the mind. Chronic depression and so on and so forth. But I think a lot of these elements have already been explored in nature. And if we look back anthropologically, people were solving the issue of medicine with their environment. In fact, what we call metropolitan medicine evolved largely from natural medicine. And in fact, today, 80% of the world, they still rely directly on plants and other compounds that are directly from plants for healthcare. I think that there is a lot to learn in there and a lot to merge, especially with the new technologies on diagnostics. And I think that that's a very exciting area to keep nature in mind. And when I said nature is like our relationship with environment, right? Bio Diego V. Bohorquez is an associate professor of medicine, associate professor in molecular genetics and microbiology, associate professor of cell biology, associate research professor in neurobiology, and an associate professor in pathology at Duke University's Department of Medicine. Bohorquez is a gut-brain neuroscientist and holds a Ph.D. from North Carolina State University. His research focus is to unveil how the brain perceives what the gut feels, how food in the intestine is sensed by our body, and how a sensory signal from a nutrient is transformed into an electrical signal that alters behavior.

New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.  

Can medications like Ozempic and Mounjaro actually do more than help you lose weight? This minisode features highlights from our full conversation, which premiered October 7th, 2025. Watch the full episode here → https://youtu.be/AcVIiy201H4?si=nlaFL3JnoZHxQVFh Dr. Rocio Salas-Whalen and I explore the difference between GLP-1, GIP, and triple-agonist drugs — and what's next in obesity medicine, how estrogen changes after 40 drive midsection weight gain and inflammation, why GLP-1s reduce cancer and Alzheimer's risk through anti-inflammatory and neuroprotective effects and how obesity and insulin resistance impact fertility and PCOS — and how GLP-1s can help.If you've ever wondered whether GLP-1s are just “weight loss shots” or a real step forward in metabolic and brain health — this “minisode” is a must-listen. *** Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 00:04  – The Probiotic GLP-1 Myth 00:19 – The “iPhone Evolution” of GLP-1 Drugs 00:52 – GLP-1 vs GIP vs Triple Agonists Explained 01:24 – Phase 3 Results & Massive Weight Loss Outcomes 01:38 – The Role of Glucagon in Weight Loss 01:56 – Menopause, Estrogen & Midlife Weight Gain0 3:06 – The “Fat Shift” After 40 04:01 – Can You Combine HRT and GLP-1s? 06:17 – “Willpower” vs Biology in Obesity 07:49 – The Genetic and Hereditary Roots of Obesity 08:57 – Breaking the Transgenerational Cycle 09:30 – Thyroid Cancer Myths and GLP-1 Safety 10:49 – GLP-1s and Breast Cancer Prevention 12:06 – Inflammation as the Root of Disease 12:28 – Neuroprotection and Alzheimer's Prevention 13:17 – GLP-1s, PCOS & Fertility Benefits 13:53 – The Positive Ripple Effect on Mental Health 14:21 – GLP-1s Reduce Alzheimer's Risk by 33% 14:58 – The Future of Metabolic Health Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a message!In this episode we will be covering Facebook Live Questions 9/8-9/14/25  from Dana's free Facebook Group Registered Dietitian Exam Study Group with Dana RD!Get the free RD Exam Prep Masterclass here. Looking for additional tutoring service? Visit my website! Shop all recorded courses at https://danajfryernutritiontutoring.teachable.comJoin the RD Exam Prep Mastery Program for access to the Situational Practice Questions,  Key Topics Review, Vocab Classes, Wed 8pest Group tutoring , study guides and a new trouble area video each week!Need a Crash Course before your exam? Check out the 4 part Pre-Exam Crash Course: Key Topics Review.

Dermatologist Dr. Erin Boh and patient advocate Brian Lehrschall discuss the challenge of managing weight, psoriasis, and psoriatic arthritis which share common inflammatory pathways and what can be done to improve all together.   Join moderator Jennifer Bomberger as she asks what is the connection between psoriatic disease and excess weight and what can be done to counter the effects of inflammatory cytokines for both with leading dermatologist Dr. Erin Boh and Brian Lehrschall who has lost over 100 pounds using diet, exercise and a GLP-1 receptor agonist. Hear Brian's story along with what is a GLP-1, how they work, and side effects.  The intent of this episode is to offer knowledge and an example of how a GLP-1 can be used successfully to improve the outcomes and management of psoriasis and psoriatic arthritis. This episode is sponsored by Lilly. A Word of Warning This episode contains information about the body, like body size, weight management, healthy eating, and lifestyle changes. If you have a history of disordered eating or are struggling with body-related mental health challenges, you might wish to explore some of our other helpful tools. There are clinical terms used by our speakers about body size or body weight that you might find triggering. Key among them is the word ‘obesity.' While it is the scientifically correct name for a disease and a common clinical term, NPF acknowledges that this word is triggering and problematic, and it is used only for the clearest of accuracy. Timestamps: (0:23) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Erin Boh and Brian Lehrschall, who has been living with psoriatic disease for over 30 years and has recently lost over 100 pounds.  (1:32) Health challenges Brian faced while trying to manage his weight, psoriasis, and psoriatic arthritis. (4:08)   Many factors contribute to psoriasis, psoriatic arthritis, and comorbidities. (5:56) Discussing the sensitive subject of losing weight and changing lifestyle. (7:57) The inflammatory pathways and connection between excess weight and psoriatic disease. (14:50) Tips for managing multiple diseases like psoriatic disease, depression, and excess weight together.  Realize “it's not your fault”. (21:32) Are low calorie or anti-inflammatory diets effective with psoriasis? (25:21) The definition of a GLP-1 (receptor agonist), how they work, and benefits in resetting how the body functions. (30:02) Brian's experience and impact of using a GLP-1. (32:08) Current and future use of GLP-1 in the management of psoriatic disease, comorbidities, and excess weight. (34:49) Be an advocate for yourself to help do all the things that will make you feel better about living with psoriasis and psoriatic arthritis. Key Takeaways: ·       Obesity or excess weight is a disease driven by an overproduction of inflammatory cytokines. ·       Psoriasis, psoriatic arthritis, and excess weight have shared pro-inflammatory disease pathways that should be considered together when identifying an effective treatment plan. ·       GLP-1 receptor agonists can be used along with dietary changes and exercise to induce weight loss that improves the body's reaction to medications used to treat psoriasis and psoriatic arthritis. Guest Bios:   Erin Boh, M.D., Ph.D. is the Joseph Chastain Endowed Chair of Clinical Dermatology at Tulane University, School of Medicine where she is also a Professor and Chairman of Dermatology. Her clinical and research focus includes photobiology, chronic diseases such as psoriasis, psoriatic arthritis, and skin cancers such as lymphoma. Dr. Boh is a past Medical Board member of the National Psoriasis Foundation and is currently a President's Council Member which represents an elite group of health care providers who are committed to the mission of the Foundation and finding a cure for psoriasis. Dr. Boh has published many articles including addressing today's topic about weight management and inflammation in psoriasis.  Brian Lehrschall has lived with psoriatic disease for three decades. He was first diagnosed with psoriasis about thirty years ago, at the age of 13 and with psoriatic arthritis at age 15. With the diagnosis came bullying which led to emotional eating. Per Brian “The more I ate, the worse the weight got.” Like most people who are overweight Brian tried to improve his health with diet and exercise. Along the way he learned about the connection between psoriasis and excess body weight. Eventually a physician recommended he try the weight loss medication GLP-1 (Glucagon-like peptide-1). Using this medication he has lost over 100 pounds and is still losing weight along with improving his overall health which includes his psoriasis and psoriatic arthritis. Brian joined the National Psoriasis Foundation in 2000 as a volunteer and has become an advocate for improving access to care and sharing his story about living with psoriatic disease. Resources: Ø  “Taking Back Control” Advance Online. M. Werbach. July 17,2025. Ø  “Is Choosing the Mediterranean Diet Right For You and Your Psoriatic Disease?” podcast episode with dermatologist Dr. Adam Ford and registered dietitian, Danielle Baham. Ø  Find the support you need through the One to One Program  

Interview with G. Caleb Alexander, MD, MS, and Hemalkumar B. Mehta, MS, PhD, authors of Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US. Hosted by Jamie Coleman, MD. Related Content: Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US The GLP-1 Era—What Comes After Bariatric Surgery?

Interview with G. Caleb Alexander, MD, MS, and Hemalkumar B. Mehta, MS, PhD, authors of Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US. Hosted by Jamie Coleman, MD. Related Content: Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US The GLP-1 Era—What Comes After Bariatric Surgery?

Lords: * Abby * https://www.thespaceuk.com/shows/2025/abby-denton-my-favorite-loser * Sid * https://linktr.ee/beamsplashx Topics: * Reading about type 1 diabetes * Saying vegetables instead of cussin' * https://jp.itch.io/mr-friendly * Winston punched his tooth out * If I Ran the Circus (excerpt) * With the power of portable PS2 emulation, I can find out how many types of games I don't like anymore Microtopics: * My Favorite Loser. * Mistakes we always keep in the show because it's more fun that way. * How to plagiarize video using Da Vinci Resolve. * A tool that automatically turns any Youtube video into a series of screenshots with captions. * Your mom threatening to sell your copy of Sonic the Hedgehog when it's explicitly labeled "not for resale" * Explaining to your mom that they're not video games, they're computer games, and she explains that video is from the Latin for "to see" * Mom paying proper deference to your clever sass before grounding you. * They're called RPGs, Mother! * Reading just enough about diabetes to be unhelpful. * Reading the diabetes owners manual. * Your $200/month Glucagon habit. * The Quick Start Guide to Diabetes, which explains that ideally you'd do such and such for your diabetic child but you probably don't have health insurance so, uh, good luck! * WiFi 7 upgrading you to gay. * Recreational glucose monitors. * The new glucose tablets coming in metric and confusing everybody. * That time Solid Snake went hypoglycemic while being tortured and bit down on his fake tooth to release the glucose capsule. * We put sugar gel in you, Solid Snake! It's going to make you slightly loopy! * An accountant who likes jogging. * Nobody knows why women have a higher incidence of eating disorders. If only we could ask them * They made a cure to diabetes 30 years ago, but you have to become the President of the United States to get it. * If Diabetes is so good, why haven't they made a Diabetes 2? * The Quick Start Guide to Diabetes explaining that people with diabetes can talk over you in a funny voice and you're not allowed to do anything about it. * Fiddling with a bloodletting device in an antique store and accidentally letting nearly all of your blood. * Phlegmletters. * What part of the body hurts least to prick with a needle. (The balls.) (Of your feet.) * Code switching halfway through explaining how you like to cuss. * How to swear at someone using vegetables. * What a load of parsnips! * Brussels Sprouts patch notes. * Brussels Sprouts: Belgium's Great Shame. * Winnipeg Manitoba sprouts. * Walking up to a stranger on the street and saying "Hey! It's a load of parsnips!" when they don't even know how you feel about parsnips. * Veggie Tales: Christ Died for our Parsnips. * Finding hilarious jokes in the text but your Bible studies group doesn't think they're very funny at all. * Refusing to apologize about a joke because someone somewhere is going to get the joke. * Why they still play old cartoons when they have Dragon Ball Z now. * Trying to find the 90s show about a kid trapped in a sitcom neighborhood that a talking dog told Abby about. * A video game where instead of having to shoot people, you talk to people. * Mr. Friendly. * Running errands for the demons. * Demon acceptance. * Can you believe Satan? What will they come up with next? * Lucifer Twocifer: Bringer of the Deuce. * Embarking on a multi-year project to have the coolest most clever minced oaths because you refuse to have basic minced oaths. * Whether it's racist to call a safecracker a Yegg. * The funniest joke you heard when you were eight. * The hobo with excellent glycemic index who lives in your shed. * Trying cat insulin and promising to report back if you die. * Hyperdontia. * Accidentally swallowing a tooth and growing a tooth tree in your tummy. * Explaining to your kid who just swallowed a tooth that it's going to bite him on the butt on the way out. * Inventing an increasingly elaborate series of fairies that cover everything that can happen to your child's teeth * What kind of degree you need to become a tooth fairy. * Going to the dentist to do a bunch of drugs and get punched in the face. * The tooth fairy talking about switching careers. * Paying for PDFs to print and put under your child's pillow when they lose a tooth. * Trying to pay a mortgage on a tooth fairy's salary nowadays. * What you're going to make Mr. Sneelock do. * A hoodwink who can't wink good. * If only we could talk to the LAPD. * Looking up the IPA pronunciation of Truffula Trees. * Anticipating the day you'll finally get to say "what it is" * Reading The Lorax in a bad David Lynch impression. * Over Forty Years of Trusted Quality at Nature's Bounty. * Seeing yourself on video and realizing you've been on the autism spectrum the whole time. * Knowing your friend only has one joke and telling a whole shaggy dog story to set up the one joke, as a gift. * The zoomers that they have nowadays. * Hello, this is my Asian man voice. * Going around the circle and everybody doing their best Asian man voice, finishing with the guy you want cancelled the most. * Spending $150 trying to connect your PlayStation 2 to a modern television. * Exhorting people to read the jokes in your pinned tweets. * Importing PS3 games – or not importing them, which is cheaper. * All the things you could've done instead of shooting Shinzo Abe. * Playing Tenchu: Wrath of Heaven and trying to change the control scene to be more like Sekiro, even though you hated Sekiro. * Freaking out because you didn't have everything figured out by the time you're 24. * Playing Bumpy Trot with your weeb girlfriend.

Boost your testosterone and transform your health with this deep dive into the world of TRT! Mark Bell and Nsima Inyang hang out with Chase Irons on Mark Bell's Power Project Podcast to break down the science behind testosterone replacement therapy, hormones, and optimizing your body.They tackle everything from managing TRT dosages, diet, and cardio to avoid side effects like bloating and high blood pressure, to strategies for building muscle and burning fat. Chase shares his insights on using peptides, GLP-1s, HGH, and even methylene blue for recovery and energy.Follow Chase on IG: https://www.instagram.com/chaseirons/Special perks for our listeners below!

00:00:00 - Surf's Up: Season 6 Episode 7Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activity and the increasing role of NITs in drug development. While introducing roundtable guests, he introduces first-time Surfer Dr. Kristina Curtis of the UK-based consultancy, Applied Behaviour Change.00:09:11 - Roundtable I: From the Global Think-Tank on SLDThis discussion starts with co-host Jörn Schattenberg discussing the history and evolution of the first four Global Think-Tanks as the focus shifts from educating medical professionals about liver disease to incorporating a broader group of stakeholders, including politicians and non-hepatologist MDs, to break down siloes and create wider awareness. Co-host Louise Campbell describes the breadth of stakeholders necessary to address this pandemic fully. She explains how her work with transient elastography and the MyLife365.me app constitutes a form of behavioral therapy. Jörn describes the test as a diagnostic and comments that the treatment is what health professionals do with the results. Kristina says that the behavioral change that results comes from well-delivered feedback. She describes "hybrid interventions, digital interventions with a human in the loop." Louise discusses results from the EASL late-breaker that support these findings and goes on to discuss the role AI can play in medical practices.00:23:50 - Newsmaker: Jose Willemse, Dutch Liver Patients Association This discussion covers two primary topics: (1) the Amsterdam screening activity that took place during EASL. Jose describes the phenomenal level of interest in this activity, in which hepatologists and APPs scanned 400 people per day for MASLD and MASH. Boosted by significant mass publicity in Amsterdam, the number of people seeking screening exceeded the 400/day quota, with some arriving in line hours before the scheduled start time and others traveling for hours to reach the site. Jose believes that with adequate publicity, efforts like these could be replicated around the world, but that the healthcare system lacks the necessary resources to do so. In terms of patient care, Jose emphasized the importance of sensitive yet frank conversations and helping patients appreciate the successes they are achieving. 00:53:45 - Roundtable II: NITs Increasing Role in Drug Development Sven Francque and Naim Alhouri joined Louise, Jörn and Roger for this roundtable, although Naim had dropped off by this time. The conversation starts with Louise noting that the goal of therapy is not simply to treat MASLD, but to achieve overall metabolic health, of which MASLD is a key component. Jörn states that we are on the path toward conducting clinical trials entirely with NITs as disease markers, which he describes as a "game changer" and Louise terms "exciting." She asks whether NITs can serve as the only trial surrogate. Jörn and Sven agree that we are not at that point yet, but we are headed in that direction. Jörn asserts that "nothing" will replace outcomes as the prerequisite for full approval and mentions the VCTE study group as demonstrating that a large NIT-based trial can prove effects on disease. Louise cautions that operator competency is a key, if overlooked, criterion for this kind of activity. Sven concurs and states that repeat measures are crucial in managing disease. Jörn notes that practices can serve as centers of care, but will need support from nutritionists and other professionals. 01:06:08 - Business ReportRoger highlights special September programming, indicates that new sponsors are on the way, and asks how many listeners find SurfingMASH on YouTube. 

Dr. Spencer Nadolsky joins Ethan on the American Glutton Podcast to dive into the revolutionary impact of GLP-1 drugs on obesity and cardiometabolic health, exploring their benefits, risks, and societal implications. From debunking myths about weight loss to discussing emerging treatments like myostatin inhibitors, they tackle the science and real-world applications head-on. The conversation also touches on the future of these medications, their potential to prevent weight gain, and the importance of combining them with lifestyle changes like resistance training.SHOW HIGHLIGHTS00:00 - Introduction and Catching Up00:35 - Obesity as a Choice and GLP-1 Drugs01:58 - Misuse of GLP-1s and Social Media Hype05:08 - The Science Behind GLP-1 and Incretin Effect07:37 - How GLP-1 Drugs Work for Weight Loss10:00 - Benefits vs. Risks of GLP-1 Drugs11:57 - Common Side Effects and Nausea Discussion13:15 - Fatigue and Anhedonia as Side Effects14:54 - Fat Cell Memory and Weight Regain17:41 - GLP-1s as a Breakthrough for Obesity19:33 - Comparing Risks of GLP-1s to Other Drugs20:24 - Big Pharma and Advisory Boards23:57 - Importance of Protein and Resistance Training27:34 - Myostatin Inhibitors and Muscle Growth31:39 - Timeline for New Drug Approvals33:31 - Drug Costs and Accessibility37:51 - Comparing GLP-1 Drugs and Zepbound39:57 - Glucagon and Triple Agonist Drugs41:58 - Future of GLP-1s in Preventing Weight Gain43:43 - Microdosing and Anti-Inflammatory Effects44:33 - GLP-1s and Type 1 Diabetes Considerations48:50 - Historical Context and Obesity Trends52:37 - Moralizing Weight and Pharmaceutical Solutions54:03 - Closing Thoughts and Future Support Hosted on Acast. See acast.com/privacy for more information.

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Plant-Based Diets In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. 0:19 – The connection between diet and health 4:05 – Organic versus non-organic: does it matter? 4:56 – Plant-based diets and improved erectile function 7:19 – Stigma and undertreatment in men's health 9:14 – Research from the Prostate Cancer Foundation 11:57 – The growing role of lifestyle medicine 14:49 – Glucagon-like peptide-1 (GLP-1) agonists in urological health  

July 2025 Journal Club Podcast Title: Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study To read journal article: https://journals.lww.com/neurosurgery/fulltext/2025/07000/perioperative_glucagon_like_peptide_1_agonist_use.9.aspx Author: Konstantinos Margetis Guest Faculty: Stephen Kalhorn Moderator: Brian Saway Committee Co-Chair: Kimberly Hoang

Dr. Centor discusses the effectiveness and safety of glucagon-like peptide-1 receptor agonists for weight loss in the absence of diabetes with Ms. Areesha Moiz.

In this episode of the PFC Podcast, Dennis and Doug delve into the complexities of bradyarrhythmias, discussing their recognition, causes, and treatment options. They explore the importance of vital signs, differential diagnosis, and the various pharmacological and electrical interventions available for managing bradycardia. The conversation also touches on the implications of overdoses and the long-term management of patients with bradyarrhythmias, emphasizing the need for a comprehensive approach in emergency medicine.TakeawaysRecognizing bradycardia involves checking vital signs and symptoms.Not all bradycardias are the same; context matters.Altered mental status can indicate shock in bradycardia cases.Lyme disease is a significant cause of bradycardia in younger populations.Narcotic overdose can lead to bradycardia and requires immediate attention.Atropine is a quick and handy treatment for bradycardia.Transcutaneous pacing is a common emergency intervention.Dopamine is preferred for its targeting of heart rate in bradycardia.Glucagon is an expensive but necessary treatment for beta-blocker overdose.Treating hypoxia is crucial before addressing bradycardia.Chapters00:00 Introduction to Bradyarrhythmias03:01 Recognizing Bradycardia and Its Symptoms06:14 Causes of Bradycardia09:02 Differential Diagnosis in Bradycardia11:57 Stabilization and Treatment Approaches14:46 Pharmacological Interventions for Bradycardia17:59 Electrical Interventions: Pacing Techniques20:55 Managing Overdoses and Bradycardia23:48 Long-term Management and Follow-up26:54 Conclusion and Key TakeawaysLink to full podcast:⁠⁠https://creators.spotify.com/pod/show/dennis3211/episodes/Prolonged-Field-Care-Podcast-228-DImE-e32aek2⁠⁠Thank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠⁠

¿Ozempic es solo para bajar de peso? La respuesta es mucho más profunda. En este video te explico, con evidencia científica clara, lo que realmente sucede en tu cuerpo cuando tomas Ozempic (semaglutida): -Cómo regula el apetito en tu cerebro -Cómo mejora tu digestión y metabolismo -Por qué reduce el "ruido de comida" -Y cómo puede devolverte el control sobre tu salud metabólica ¡Suscríbete a este podcast en tu plataforma favorita para no perderte nada!

00:00:00 Surf's Up, Season 6, Episode 6.On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Development, Part 2The second portion of the Drug Development roundtable primarily focuses on three key issues. The first, uptake of resmetirom, starts with Naim Alkhouri discussing his experience in the Arizona Liver Health Clinics with over 650 patients in the year since resmetirom was approved and shifts to the various European panelists (Jörn Schattenberg, Louise Campbell and Sven Francque) estimating when it might be approved in their countries and how widely it might be reimbursed.  The second topic, incretin agonists, focuses on exciting prospects for other incretin agonists in development, as well as some semaglutide combination therapies. The third, NIT clinical trials, covers prospects that non-biopsy clinical trials might be approved sometime in the near future.00:16:20 - Remembering Stephen Harrison I: An Interview with Summit Clinical Research CEO Gail HinksonSummit CEO Gail Hinkson joins Roger Green for the first time on SurfingMASH to discuss her business partner. Gail discusses how the two originally formed Pinnacle Clinical Research and how Pinnacle led to Summit. She proceeds to discuss the current size and reach of both Pinnacle and Summit. Focusing on Summit, Gail describes the company as an Integrated Research Organization (IRO), highlighting its distinct role within the MASH firmament. In the final section of the interview, Gail discusses how Stephen's personality, goals, and vision continue to live on at Summit today.00:34:31 - Remembering Stephen Harrison II: An Interview with Naim Alkhouri Announcing That He Is Joining SummitNewly announced Summit Chief Academic Officer Naim Alkhouri joins this episode for a second time, but in a very different role. Naim discusses his personal history with Stephen and what he loved and respected about his "dear friend." He then makes a major announcement: he is joining Summit as Chief Academic Officer. He shares the many elements of this role, particularly his excitement that Summit can become the entity that educates a wide range of healthcare and commercial professionals on what MASH is and how it is treated. The scope of this vision, combined with what Gail discussed, portrays a level of energy, ambition and vision worthy of Stephen Harrison.00:55:55 - ConclusionAs part of this memorial week, Roger Green forgoes the usual business report, which will return next week.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes.

Send us a textToday we are releasing a bonus episode!This is my recent appearance on the Low Carb and Fasting YouTube Channel hoisted by Nayiri Mississian!  We were fortunate enough to host Nayiri on our podcast on episode 437 and episode 737 of Boundless Body Radio!As always, it was a fun chat, and I'm always so grateful to be a guest on someone else's show!Nayiri Mississian is an independent nutrition researcher, who has no associations with the food industry, pharmaceutical industry or any politically powered nutrition organizations. Nayiri shares her scientific information with the followers in her members-only exclusive Facebook groups, which promote the low carbohydrate/low insulin lifestyle as supported by scientific evidence. The low carb and fasting group members have free access to summarized information posts, recipes, tips, and weekly live videos. Nayiri is the host of the fantastic Low Carb and Fasting Podcast!Find Nayiri at-https://lowcarbandfasting.com/TW- @NTSTranslationFB- @LOW CARB & FASTINGPodcast- Low Carb and Fasting PodcastNayiri's amazing and very helpful blood glucose conversion charts!Stephen Thomas, known online as the UK Carnivore, debunks and dispels many popular myths about nutrition, fitness, and aging. In the past, while eating high-carbohydrate, low-fat diet, Stephen was a semi-professional soccer player, won a singles tennis tournament, and had run some middle-distance races, but his health was poor, as he had experienced frequent colds, and struggled with several other health issues.Find Stephen at-https://www.theukcarnivore.com/IG- @theukcarnivoreYT- @Coach Stephen BSc HonsPodcast- The UK Carnivore ExperienceFind Boundless Body at- myboundlessbody.com Book a session with us here!

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

Can a nitro slurry help with food bolus impaction? Glucagon and effervescent beverages have limited evidence for benefit. Can an old drug used in a new way help these patients?

Ozempic and other GLP-1 drugs have exploded in popularity largely due to their effectiveness in treating type-2 diabetes and, perhaps more significantly, their weight-loss effects. But what do we know about these drugs and how they work? We're joined by Dr. Daniel J. Drucker, Dr. Sanjeev Sockalingam, and registered dietician Nishta Saxena.See omnystudio.com/listener for privacy information.

In this Huberman Lab Essentials episode, I explain how hormones regulate hunger, appetite and feelings of satiety (fullness), along with strategies to help control appetite. I describe how the body senses nutrient levels and how the brain processes these signals to stimulate hunger or suppress appetite. I also discuss how certain foods can help curb hunger, while processed foods and emulsifiers can interfere with satiety signals, leading to overeating. Additionally, I cover how lifestyle factors such as exercise and meal timing regulate blood glucose levels, which in turn impact hunger and appetite. Huberman Lab Essentials episodes are approximately 30 minutes long and focus on essential science and protocol takeaways from past Huberman Lab episodes. Essentials will be released every Thursday, while our full-length episodes will continue to be released every Monday. This Huberman Lab Essentials is from the full-length Huberman Lab episode, “How Our Hormones Control Our Hunger, Eating & Satiety.” Read the full episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David Protein: https://davidprotein.com/huberman Mateina: https://drinkmateina.com/huberman LMNT: https://drinklmnt.com/huberman For all Huberman Lab sponsors, visit hubermanlab.com/sponsors. Timestamps 00:00:00 Huberman Lab Essentials; Hunger & Appetite 00:00:56 Hunger, Hypothalamus, Cortex & Mouth 00:04:46 Sponsor: David Protein 00:06:02 Melanocyte-Stimulating Hormone, AgRP Neurons, Ghrelin, Tool: Regular Meal Timing 00:10:13 Cholecystokinin (CCK), Tool: Omega-3s, Amino Acids & Blunting Appetite 00:13:26 Sponsor: AG1 00:14:30 Highly-Processed Foods, Emulsifiers, Tool: Whole Foods & Satiety Signals 00:19:10 Insulin, Glucose, Type 1 & 2 Diabetes 00:22:16 Sponsor: Mateina 00:23:41 Insulin & Glucagon, Tools: Food Order, Movement & Blood Glucose 00:27:26 Tool: Exercise & Stable Blood Sugar 00:29:38 Metformin, Ketogenic Diet, Blood Glucose 00:31:59 Sponsor: LMNT 00:33:16 Diabetes, Urine & Blood Sugar 00:35:40 Caffeine, Tool: Yerba Mate, Glucagon-Like Peptide -1 (GLP-1), Appetite 00:38:49 Recap & Key Takeaways Disclaimer & Disclosures

How do GLP-1 receptor agonists and metformin affect glaucoma risk in patients with Type 2 diabetes? Join Dr. Ike Ahmed and Jawad Muayad as they discuss the data on diabetes treatments and glaucoma risk with Dr. Emily Schehlein. From their Ophthalmology article, “Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes.” Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes. Muayad, Jawad et al. Ophthalmology. In press.

Sarah shares her low BG stories.  JUICE CRUISE 2025 Learn about the Medtronic Champions Try delicious AG1 - Drink AG1.com/Juicebox I Have Vision Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.  

Laura saved a man with her glucagon!  JUICE CRUISE 2025 Eat Hungryroot Screen It Like You Mean It Eversense CGM Learn about the Medtronic Champions This BetterHelp link saves 10% on your first month of therapy Try delicious AG1 - Drink AG1.com/Juicebox I Have Vision Use code JUICEBOX to save 40% at Cozy Earth  Get Gvoke HypoPen CONTOUR NextGen smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.  

Send us a textNayiri Mississian is a former guest on our show! Check out her first appearance on episode 437 of Boundless Body Radio!Nayiri Mississian, MHP is an independent nutrition researcher, who has no associations with the food industry, pharmaceutical industry or any politically powered nutrition organizations. She has been involved in nutrition research since 2015. Nayiri shares her scientific information with the followers in her members-only exclusive Facebook groups, which promote the low carbohydrate/low insulin lifestyle as supported by scientific evidence.This is the only lifestyle, as shown in medical science, that prevents or reverses insulin resistance, thus dramatically reducing one's chances of developing metabolic illnesses such as type 2 diabetes, obesity, hypertension, heart disease, Alzheimer's, and even some types of cancer.The low carb and fasting group members have free access to summarized information posts, recipes, tips, and weekly live videos. Nayiri is the host of the Low Carb and Fasting channel on YouTube, which I was honored to be hosted on. She is an avid gardener in the summer when the weather cooperates!Find Nayiri at-https://lowcarbandfasting.com/YT- Low Carb and Fasting PodcastFB- @LOW CARB & FASTINGNayiri's amazing and very helpful blood glucose conversion charts!Find Boundless Body at- myboundlessbody.com Book a session with us here!

Send us a textDr. Ryan Attar is a returning guest on our show! Be sure to check out his first appearance on episode 186 of Boundless Body Radio!Dr. Ryan Attar is an expert in managing Type 1 diabetes. Dr. Attar is a veteran of the US Army, and after serving overseas, Dr. Attar developed Type 1 diabetes, and was medically discharged from the Army after nearly 6 years of service.After the military, Dr. Attar decided to embark on a new career to aide those with diabetes and other health issues. He graduated in 2017 from the University of Bridgeport with a Doctorate in Naturopathic Medicine and a Master's in Human Nutrition.Dr. Attar has been LIVING and THRIVING with diabetes for 12 years, and helps his patients achieve better blood glucose, A1c and weight loss goals. He is very active in the TypeOneGrit online diabetes community, a group that was studied in 2018 in the journal Pediatrics. He has written several articles on the diabetes website Diabetes Daily.When not practicing medicine, Dr. Attar is an avid traveler, having been to 75 countries. Dr. Attar also enjoys fitness, weightlifting and is currently a blue belt in jiujitsu!Find Dr. Attar at-https://drattar.com/TW- @ryanattarThe Diabetes Solution documentary!Find Boundless Body at- myboundlessbody.com Book a session with us here!

Kamyar Ghabili, MD, discusses the AJR article by Nelson et al. identifying patterns of changes in CT-based body composition measures after initiation of semaglutide therapy. ARTICLE TITLE - Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Agonist) Therapy

We delve into the management of esophageal foreign body obstructions, a common yet often misunderstood medical emergency. We discuss the symptoms and causes of esophageal food impactions, sometimes referred to as 'Steakhouse Syndrome,' and differentiate it from tracheal obstructions. We explore the protocols, potential treatments, and if there's any rationale behind treatments such as glucagon administration. Join us as we also share real-life scenarios to better illustrate the challenges and solutions when dealing with such medical cases.   Resources and links This episode was inspired by an article on EMSAirway.com- Friday Night Lights- Shift 9 Steak Night  EMScast15 - code for 15% off an awesome pair of sunglasses  Help Us By Filling Out Our Audience Survey  Medic Box - awesome medical gear shipped directly to your door  Articles- American Society for Gastrointestinal Endoscopy- Guidelines for ingested foreign bodies   Glucagon for Relief of Acute Esophageal Foreign Bodies and Food Impactions: A Systematic Review and Meta-Analysis.   Efficacy of cola ingestion for oesophageal food bolus impaction: open label, multicentre, randomised controlled trial   Conservative management of oesophageal soft food bolus impaction   Esophageal Food Impaction: A Retrospective Chart Review Food Bolus Impaction- Question and Answer Review     Guest/Cast/Crew information- Host- Ross Orpet, Will Berry    Catch up with us after the show Instagram- @emscast Twitter- @ems_cast Website- www.emspodcast.com   00:00 Introduction to Esophageal Foreign Bodies 00:43 Audience Survey and Sunglasses Giveaway 01:46 Interview with Contest Winner 06:11 A Choking Incident at Mile High Stadium 09:02 Discussion on Esophageal Obstructions 11:46 Life-Saving Story at Denver International Airport 13:28 A Life-Saving Outcome 14:11 The Choking Incident at the Tavern 14:57 Assessing the Patient's Condition 19:38 Understanding Esophageal Food Impaction 21:49 Treatment Options and Challenges 29:01 The Role of Endoscopy 37:45 Managing Esophageal Impactions in the Field 39:32 Final Thoughts

Free Energy Balance Food Guide: https://jayfeldmanwellness.com/guide   The Nutrition Blueprint: https://mikefave.com/the-nutrition-blueprint/   Danny's Website: https://t.me/dannyroddy   Danny's Substack: https://dannyroddy.substack.com/   Timestamps: 0:00 – intro 0:33 – why we started this podcast 6:25 – our take on Bryan Johnson's Longevity Blueprint and problems with biohacking 12:13 – whether we should adopt any of the strategies from Bryan Johnson's Blueprint to achieve optimal health 14:50 – the cost of continually being in a caloric deficit and why this does not increase longevity 21:06 – issues with eating hard-to-digest foods and whether supplements can make up for missing nutrients in the diet 22:13 – the importance of avoiding reductionistic thinking around supplements touted for weight loss benefits 28:00 – potential pros and cons of Bryan Johnson's Blueprint and how to measure health 32:39 – Bryan Johnson's supplement protocol 41:09 – how low-carb diets negatively affect NAD+ to NADH ratios and estrogen status 46:20 – whether body fat percentage and cholesterol levels can be too low 52:20 – what is stress? 1:03:20 – issues with hormesis and the idea that stress is beneficial 1:07:34 – whether avoiding stress is possible and how to develop resilience to stress 1:13:17 – addressing Marty Kendall's response to our take on glucagon and insulin 1:24:17 – glucagon's short-term and long-term effects on metabolic function 1:26:46 – glucagon's role in insulin resistance and type 2 diabetes 1:37:16 – metabolic dysfunction as a driver of insulin resistance 1:41:06 – whether we need to be concerned about wasting energy on hormone production 1:44:50 – whether we should always try to avoid gluconeogenesis 1:51:45 – how to use carbohydrates to stabilize your blood sugar 1:56:11 – habit stacking, simplifying supplementation, and adopting a long-term mindset when it comes to health

The 2024 Lasker–DeBakey Clinical Medical Research Award has been presented for the discovery of GLP-1 and its application to the treatment of obesity. Lasker winner Svetlana Mojsov, PhD, discusses her role in this innovative discovery and more with JAMA Senior Editor Anne Rentoumis Cappola, MD, ScM. Related Content: Chemistry Matters—From a Putative Peptide to Effective Treatments for Diabetes and Obesity Discovery of cGAS as a DNA-Sensing Enzyme That Triggers Inflammation GLP-1 for Treating Obesity—Origin, History, and Evolution AIDS in Africa—Impact of Research

In this episode, we're diving deep into GLP-1 agonists, a topic that has sparked considerable debate within the fitness and health communities. Our special guest, Anthony Castor, brings a wealth of knowledge as the first non-physician to earn a fellowship with the Seed Scientific Research and Performance Institute. Together, we'll address controversies, debunk myths, and uncover the multi-faceted benefits of GLP-1 agonists far beyond their well-known role in weight loss and diabetes management. We'll explore their neuroprotective effects, benefits in managing neurodegenerative diseases like Alzheimer's and Parkinson's, and their surprising impact on cognitive decline, addiction, and ADHD. Moreover, we'll break down complex mechanisms, historical context, and real-world applications in an easily digestible format. Stay tuned as we demystify GLP-1 agonists and reveal how they can enhance not only physical but also mental resilience. Anthony Castor, a health advocate and educator, delves into the intricate world of peptides and their multifaceted benefits.   With a passion for making complex biochemical processes understandable, Anthony focuses on the potent impacts of GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and myelin, among others. By demystifying how these peptides interact and function together, Anthony aims to shift public perception and drive forward significant improvements in health. Known for his use of analogies to clarify scientific concepts, Anthony is committed to educating people on the transformative potential of these sophisticated biochemical tools. Anthony's Website: https://www.castoremethod.com Instagram: https://www.instagram.com/anthonycastore/   Join Duffin Community & Education: https://www.skool.com/endless-evolution-8560/about www.chrisduffin.com

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad.  The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.   In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.   Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.   The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.   The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.   For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed “substantial improvements in blood glucose outcomes and overall quality of life,” said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. “For the larger epidemic of type 2 diabetes, we're failing right now,” Califf said. “I don't say that lightly.” A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX   Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.   The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.   PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.   The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon!

Scott and Jenny Smith define diabetes terms In this Defining Diabetes episode we define glucagon. This BetterHelp link saves 10% on your first month of therapy Try delicious AG1 - Drink AG1.com/Juicebox I Have Vision Use code JUICEBOX to save 30% at Cozy Earth  Get Gvoke HypoPen Eversense CGM Learn about the Medtronic Champions CONTOUR NextGen smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  A full list of our sponsors  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.  

Paul Edick and Sean Saint are CEOs of thier respective companies (Beta Bionics and Xeris). Today we talk about their new relationship and their desire to create a bi-hormonal insulin pump. Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey Free 14 Day Trial of Aura Eversense CGM Learn about the Medtronic Champions This BetterHelp link saves 10% on your first month of therapy Try delicious AG1 - Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  A full list of our sponsors  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.

***JOIN THE MASTER YOUR FASTING CHALLENGE THAT STARTS May 8th, 2024!*** New to fasting or want to get back on track? Struggling to break through a plateau? Ready to finally stop obsessing about your diet? Let's kick off spring time and prep for summer with intention, habit-building, and fast-tracking your fasting results! We'll GUIDE you how to FAST to LOSE FAT for good, and use 'fast cycling' to achieve uncommon results! Join us on May 8th for the Master Your Fasting Challenge!   REGISTER HERE! Click the Link for DATES, DETAILS, and FAQs! MAY 8th CHALLENGE REGISTRATION LINK In today's episode, we dive into a detailed conversation about a study published in the Journal of Nutrients, comparing the effects of a high carbohydrate versus a high-fat shake on metabolism and glycemic control when used to break a 38-hour fast. Dr. Benjamin Bickman completed this study. The study suggests that the type of nutrients consumed when breaking a fast significantly impacts metabolic health. It highlights that low-carb, high-fat shakes are more beneficial for maintaining ketosis and glycemic control compared to high-carb, low-fat shakes. The findings underscore the importance of food choices in optimizing fasting strategies for better health outcomes. They emphasize that what you eat and when you eat matters greatly for those practicing intermittent fasting or time-restricted eating. FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS! Learn how to RAMP UP into longer fasting windows! Gain insights into the non-weight loss benefits of fasting! Personalize your own fasting schedule and consistent FAT LOSS results! Get answers to what breaks a fast, how to break a fast, and tips and tricks to accelerate your fasting wins! THE BLUEPRINT TO FASTING FOR FAT LOSS DOWNLOAD Get your FREE BOX OF LMNT hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase here! Get 30% off a Keto-Mojo blood glucose and ketone monitor (discount shown at checkout)! Click here! Let's continue the conversation. Click the link below to JOIN the Fasting For Life Community, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! Fasting For Life Community - Join HERE New to the podcast and wondering where to start? Head to the website and download our Fast Start Guide, 6 simple steps to put One Meal a Day Fasting (OMAD) into practice! Get our NEW sleep guide here! SLEEP GUIDE DIRECT DOWNLOAD If you enjoy the podcast, would you please tap on the stars below and consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Research Links: https://www.mdpi.com/2072-6643/16/1/164